MicroRNA-21在胰腺癌发病和诊治中作用的研究  

Role of MicroRNA-21 in Pathogenesis,Diagnosis and Treatment of Pancreatic Cancer

作　　者：赵秋艳[1] 陈素敏[1] 任迎春[1] 李百文[1] 

机构地区：[1]上海交通大学医学院附属第一人民医院消化内科,201620

出　　处：《胃肠病学》2017年第8期502-505,共4页Chinese Journal of Gastroenterology

基　　金：国家自然科学基金项目(81572316)

摘　　要：胰腺癌起病隐匿,具有高度侵袭性,恶性程度高,预后极差,因此亟需寻找胰腺癌的早期诊断标记物,研发能有效治疗胰腺癌的靶向药物。微RNA(miRNA)是一类长度约为18~25 nt的非编码小分子单链RNA,在胰腺癌中高表达,参与胰腺癌细胞的增殖、分化、凋亡、侵袭和转移,并与胰腺癌的不良预后和化疗抵抗有关。miRNA-21作为诊断和治疗胰腺癌的新靶点,已成为目前临床研究的热点。本文就miRNA-21在胰腺癌发病和诊治中作用的研究进展作一综述。Pancreatic cancer is characterized by high invasiveness,high malignancy and poor prognosis. Therefore,it is urgent to find biomarkers for early diagnosis and to develop targeting drugs for treatment of pancreatic cancer. MicroRNAs（ miRNAs） are single-stranded,non-coding small RNA molecules with a length of 18-25 nucleotides and are highly expressed in pancreatic cancer. MiRNAs play important roles in cell proliferation,differentiation,apoptosis,invasion and metastasis,and are associated with adverse prognosis and resistance to chemotherapy in pancreatic cancer. As a new target for diagnosis and treatment of pancreatic cancer,miRNA-21 has become the hot spot of clinical research. This article reviewed the advances in studies on miRNA-21 in the pathogenesis,diagnosis and treatment of pancreatic cancer.

关 键 词：胰腺肿瘤 微RNAS 发病机制 诊断 治疗 

分 类 号：R735.9[医药卫生—肿瘤]